An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

Inclusion Criteria: * Patients must be willing and able to complete all study-specific procedures and visits * Healthy patients, as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram, and clinical laboratory determinations * Body mass index (BMI) of 18 to 32 kg/m2, inclusive, at screening * Normal renal function at screening Exclusion Criteria: * Any medical condition that presents a potential risk to the participant and/or may compromise the objectives of the study, including a history of or active liver disease * Current or recent (within 3 months of study drug administration) gastrointestinal disease that could impact upon the absorption of study drug * History or presence of clinically significant acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicemia) within the 3 months prior to screening * Additional criteria may apply